Company Filing History:
2 out of 2,009 
1 out of 3,539 
Years Active: 2018-2022
Title: Innovations in Immunotoxin Development by Charles Pegram
Introduction
Charles Pegram is an accomplished inventor based in Durham, NC (US), known for his significant contributions to the field of immunotoxin research. He holds two patents that focus on innovative therapies for brain tumors, particularly targeting specific receptors overexpressed in glioblastomas. His work has the potential to advance treatment options for patients suffering from this aggressive form of cancer.
Latest Patents
Pegram's latest patents include the production of D2C7-(scdsFv)-PE38KDEL, a recombinant exotoxin A-based immunotoxin. This immunotoxin targets both wild-type epidermal growth factor receptor (EGFRwt) and the mutant EGFR variant III (EGFRvIII) proteins. A good laboratory practice (GLP) manufacturing process was developed to produce sufficient material for a Phase I/II clinical trial. The D2C7-IT was expressed under the control of the T7 promoter in BLR (λ DE31) and produced through a 10 L batch fermentation process. The purification process achieved a yield of over 300 mg of purified protein. Additionally, he developed a dual-specific immunotoxin for brain tumor therapy, which demonstrated significant potential in preclinical studies.
Career Highlights
Throughout his career, Pegram has worked with prestigious institutions such as Duke University and the National Institutes of Health, a component of the US Department of Health & Human Services. His research has focused on developing innovative therapies that leverage the specificity of immunotoxins to target cancer cells effectively.
Collaborations
Pegram has collaborated with notable colleagues, including Darell D Bigner and Vidyalakshmi Chandramohan, to advance the understanding and application of immunotoxins in cancer therapy.
Conclusion
Charles Pegram's work in the field of immunotoxins represents a significant advancement in cancer treatment, particularly for brain tumors. His innovative approaches and collaborations have the potential to improve patient outcomes and pave the way for future research in this critical area.